

**L. Allen Kindman**, **MD, FACC**, is a distinguished professional with an extensive background in cardiovascular disease, data analytics and digital transformation. He has demonstrated exceptional strategic and innovative leadership skills, contributing significantly to the fields of clinical trial design, therapeutic pharmaceuticals, and medical devices. At IQVIA, Dr. Kindman played a pivotal role in leveraging real-world data, artificial intelligence, and machine learning for clinical trial feasibility and protocol optimization. He is also a skilled medical monitor.

From 2017 to 2023, Dr Kindman was Vice President for Protocol, Patient, and Site Feasibility at IQVIA, where he oversaw strategy development and introduced innovative analytical approaches to clinical trials. Before this, he was a Medical Director at the Cardiovascular and Metabolic Therapeutic Science and Strategy Unit where he was a medical monitor and medical strategist. Prior to IQVIA, he was a Clinical Professor of Medicine at the University of North Carolina, and established a solo cardiology practice in a rural, medically underserved region. While in practice, he served as an investigator for pharma and device trials. Prior to clinical practice, Dr Kindman was an Assistant Professor of Medicine and Cell Biology at Duke Medical Center.

Dr. Kindman is board certified in Internal Medicine and Cardiovascular Disease. He completed residency, cardiovascular fellowship and post-doctoral work at Stanford University Medical Center, an internship at New York-Presbyterian Medical Center, and medical school at Icahn-Mount Sinai School of Medicine.